Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease.
暂无分享,去创建一个
M. Gladwin | J. Shelhamer | P. Munson | N. Raghavachari | R. Danner | C. Logun | J. Beigel | J. Barb | A. Suffredini | Shefali Talwar | M. Jison
[1] T. W. Anderson,et al. An Introduction to Multivariate Statistical Analysis , 1959 .
[2] N. Bodyak,et al. Carbon monoxide suppresses arteriosclerotic lesions associated with chronic graft rejection and with balloon injury , 2003, Nature Medicine.
[3] G. Vercellotti,et al. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. , 2000, Blood.
[4] E. Salido,et al. Isolation of a new gene from the distal short arm of the human X chromosome that escapes X-inactivation. , 1992, Human molecular genetics.
[5] H. D. Hochstein,et al. Dose-related inflammatory effects of intravenous endotoxin in humans: evaluation of a new clinical lot of Escherichia coli O:113 endotoxin. , 1999, The Journal of infectious diseases.
[6] H. Bunn. Pathogenesis and treatment of sickle cell disease. , 1997, The New England journal of medicine.
[7] S. Taylor,et al. In vivo production of type 1 cytokines in healthy sickle cell disease patients. , 1999, Journal of the National Medical Association.
[8] P. Lane. Sickle cell disease. , 1996, Pediatric clinics of North America.
[9] L. Haywood,et al. Myocardial infarction in sickle cell disease. , 1996, Journal of the National Medical Association.
[10] M. Maines,et al. The heme oxygenase system and cellular defense mechanisms. Do HO-1 and HO-2 have different functions? , 2001, Advances in experimental medicine and biology.
[11] M. Gladwin,et al. Divergent Nitric Oxide Bioavailability in Men and Women With Sickle Cell Disease , 2003, Circulation.
[12] T. Arends,et al. Levels of tumor necrosis factor alpha/cachectin (TNF alpha) in sera from patients with sickle cell disease. , 1993, Acta haematologica.
[13] D. Page,et al. Functional coherence of the human Y chromosome. , 1997, Science.
[14] Ash A. Alizadeh,et al. Individuality and variation in gene expression patterns in human blood , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[15] M. Caligiuri,et al. Interleukin 15: biology and relevance to human disease. , 2001, Blood.
[16] J. Ingwall,et al. Cardiac-Specific Expression of Heme Oxygenase-1 Protects Against Ischemia and Reperfusion Injury in Transgenic Mice , 2001, Circulation research.
[17] R. Hebbel. Perspectives series: cell adhesion in vascular biology. Adhesive interactions of sickle erythrocytes with endothelium. , 1997, The Journal of clinical investigation.
[18] A. Skoultchi,et al. Manipulating the onset of cell cycle withdrawal in differentiated erythroid cells with cyclin-dependent kinases and inhibitors. , 2000, Blood.
[19] 宁北芳,et al. 疟原虫var基因转换速率变化导致抗原变异[英]/Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A , 2005 .
[20] M. Monk,et al. Regulation of X-Chromosome Inactivation in Development in Mice and Humans , 1998, Microbiology and Molecular Biology Reviews.
[21] D. Saunders,et al. Myocardial infarction in sickle cell anemia , 1984, American journal of hematology.
[22] C. Brugnara,et al. Hydroxyurea and sickle cell disease: a chance for every patient. , 2003, JAMA.
[23] James L. Park,et al. Heme oxygenase-1 protects against vascular constriction and proliferation , 2001, Nature Medicine.
[24] H. Farber,et al. Role of free radicals in the pathogenesis of acute chest syndrome in sickle cell disease , 2001, Respiratory research.
[25] T. Arends,et al. Levels of Tumor Necrosis Factor α/Cachectin (TNFα) in Sera from Patients with Sickle Cell Disease , 1993 .
[26] T. Wun,et al. Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease. , 2002, Clinical and laboratory haematology.
[27] O. Platt,et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. , 1994, The New England journal of medicine.
[28] J. Bischof,et al. Transgenic sickle mice have vascular inflammation. , 2003, Blood.
[29] Scott T. Miller,et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. , 1998, Blood.
[30] D. Loukopoulos,et al. Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia. , 2001, Seminars in hematology.
[31] Manfred E. Wolff,et al. Burger's Medicinal chemistry , 1980 .
[32] M. Lyon. Genetic activity of sex chromosomes in somatic cells of mammals. , 1970, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[33] H. Croizat. Circulating cytokines in sickle cell patients during steady state , 1994, British journal of haematology.
[34] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[35] R. Warrier,et al. Tumor necrosis factor alpha in children with sickle cell disease in stable condition. , 1997, Journal of the National Medical Association.
[36] A. Choi,et al. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway , 2000, Nature Medicine.
[37] J. Grande,et al. Oxidative stress and induction of heme oxygenase-1 in the kidney in sickle cell disease. , 2001, The American journal of pathology.
[38] Scott T. Miller,et al. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease. , 1999, Pediatrics.
[39] Y. Nagashima,et al. Transfer of heme oxygenase 1 cDNA by a replication-deficient adenovirus enhances interleukin 10 production from alveolar macrophages that attenuates lipopolysaccharide-induced acute lung injury in mice. , 2001, Human gene therapy.
[40] A. Duits,et al. Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis. , 1996, Clinical immunology and immunopathology.
[41] T. Pearson,et al. Red blood cells from patients with sickle cell disease exhibit an increased adherence to cultured endothelium pretreated with tumour necrosis factor (TNF) , 1992, British journal of haematology.
[42] P. Perrotta,et al. Transcript profiling of human platelets using microarray and serial analysis of gene expression. , 2003, Blood.
[43] Jenifer L. Breshears. Silent Cerebral Infarcts in Sickle Cell Anemia: A Risk Factor Analysis. , 2000 .
[44] Anja Vogler,et al. An Introduction to Multivariate Statistical Analysis , 2004 .
[45] A. Choi,et al. Protective effects of heme oxygenase-1 in acute lung injury. , 1999, Chest.
[46] O. Castro,et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. , 1994, Blood.
[47] L. Haywood,et al. Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease. , 1992, Journal of the National Medical Association.
[48] G. Vercellotti,et al. Reperfusion injury pathophysiology in sickle transgenic mice. , 2000, Blood.
[49] C. Pegelow,et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. , 2003, JAMA.
[50] J. Alam,et al. Cellular overexpression of heme oxygenase-1 up-regulates p21 and confers resistance to apoptosis. , 2001, Kidney international.
[51] Solomon H. Snyder,et al. Biliverdin reductase: A major physiologic cytoprotectant , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[52] J. Alam,et al. Heme protein-induced chronic renal inflammation: suppressive effect of induced heme oxygenase-1. , 2001, Kidney international.
[53] M. Maines,et al. The heme oxygenase system: a regulator of second messenger gases. , 1997, Annual review of pharmacology and toxicology.
[54] R. Hebbel. Adhesive interactions of sickle erythrocytes with endothelium. , 1997, The Journal of clinical investigation.
[55] R. Myers,et al. Gender-Specific Gene Expression in Post-Mortem Human Brain: Localization to Sex Chromosomes , 2004, Neuropsychopharmacology.
[56] M. Gladwin,et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. , 2002 .
[57] A. Monaco,et al. The UTX gene escapes X inactivation in mice and humans. , 1998, Human molecular genetics.
[58] F. Rosner,et al. Myocardial infarction in sickle cell disease. , 2002, Journal of the National Medical Association.
[59] A. Choi,et al. Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. , 1996, American journal of respiratory cell and molecular biology.
[60] R. Hebbel,et al. Amendment history : Erratum ( September 2000 ) Hypoxia / reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice , 2018 .
[61] A. Duits,et al. Cytokines and Soluble Adhesion Molecules in Sickle Cell Anemia Patients during Hydroxyurea Therapy , 1998, Acta Haematologica.
[62] A. O. Durojaiye,et al. Acute phase reactants and severity of homozygous sickle cell disease , 1993, Journal of internal medicine.
[63] E. Hatzimichael,et al. The role of cytokines in sickle cell disease , 2000, Annals of Hematology.
[64] H. Farber,et al. Increased F2 isoprostanes in the acute chest syndrome of sickle cell disease as a marker of oxidative stress. , 2001, American journal of respiratory and critical care medicine.
[65] Tzong-Shyuan Lee,et al. Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice , 2002, Nature Medicine.
[66] A. Schechter,et al. Inhibition of Sickle Hemoglobin Polymerization as a Basis for Therapeutic Approaches to Sickle‐Cell Anemia , 2003 .
[67] J. White,et al. Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease. , 1980, The Journal of clinical investigation.
[68] Van,et al. A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.
[69] B. Setty,et al. Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium: potential role in sickle cell disease. , 1996, Blood.
[70] J. Raynes,et al. Is there an acute-phase response in steady-state sickle cell disease? , 1993, The Lancet.
[71] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .